In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.

Autor: Whitehead SS; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Durbin AP; Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; United States of America., Pierce KK; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America., Elwood D; Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; United States of America., McElvany BD; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America., Fraser EA; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America., Carmolli MP; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America., Tibery CM; Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; United States of America., Hynes NA; Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; United States of America., Jo M; Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; United States of America., Lovchik JM; Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; United States of America., Larsson CJ; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America., Doty EA; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America., Dickson DM; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America., Luke CJ; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Subbarao K; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Diehl SA; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America., Kirkpatrick BD; Vaccine Testing Center, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.

Publikováno v: PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2017 May 08; Vol. 11 (5), pp. e0005584. Date of Electronic Publication: 2017 May 08 (Print Publication: 2017).

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Autor: Durbin AP; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Kirkpatrick BD; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Pierce KK; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Carmolli MP; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Tibery CM; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Grier PL; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Hynes N; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Opert K; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Jarvis AP; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Sabundayo BP; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., McElvany BD; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Sendra EA; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Larsson CJ; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Jo M; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Lovchik JM; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Luke CJ; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland., Walsh MC; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Fraser EA; Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Subbarao K; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland., Whitehead SS; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2016 Sep 15; Vol. 214 (6), pp. 832-5. Date of Electronic Publication: 2016 Feb 16.

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

Autor: Kirkpatrick BD; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Durbin AP; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Pierce KK; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Carmolli MP; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Tibery CM; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Grier PL; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Hynes N; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Diehl SA; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Elwood D; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Jarvis AP; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Sabundayo BP; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Lyon CE; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Larsson CJ; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Jo M; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Lovchik JM; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore., Luke CJ; National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland., Walsh MC; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Fraser EA; Department of Medicine, Vaccine Testing Center, University of Vermont College of Medicine, Burlington., Subbarao K; National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland., Whitehead SS; National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2015 Sep 01; Vol. 212 (5), pp. 702-10. Date of Electronic Publication: 2015 Mar 22.